GILD — Gilead Sciences, Inc.
Is GILD overbought or oversold? Here is the current MarketMoodz read.
Gilead Sciences, Inc. (GILD) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $167.58. The rating moved from Neutral to Overbought on November 12, 2026.
- Public ratingOverbought (as of November 17, 2026)
- Last close$167.58
- Last changeMoved from Neutral to Overbought on November 12, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - General
See all overbought Healthcare stocks →
AI analysis
Gilead shows a strong, cash-generative antiviral core and a diversified set of businesses (including oncology/cell therapy) that support stable cash flow, R&D investment and M&A optionality. Large-cap pharma sector flows and the company’s dividend/return capacity underpin near-term investor interest, while partnership activity and pipeline milestones provide catalysts. Key weaknesses are revenue exposure to lifecycle pressures, competitive dynamics in HIV and other areas, regulatory/payer risk, and potential sentiment headwinds from insider selling or clinical setbacks. Overall outlook balances steady income generation with upside from successful pipeline or strategic deals, offset by medium-term execution and competitive risks.
Key factors
- Leading, cash-generative antiviral franchise (HIV treatments like Biktarvy) that provides stable free cash flow and funding for R&D and M&A
- Diversified portfolio including oncology/cell therapy (Kite), antivirals, and emerging pipeline assets supporting multi-year revenue visibility
- Defensive large-cap pharma positioning amid sector flows into big pharma names; investors favor steady earnings and dividend/cash returns
- Ongoing business development and partnership activity increases optionality for near-term catalytic readthroughs
- Recent partnership to expand access to experimental Ebola prevention drug demonstrates global health positioning and goodwill
- Reasonable valuation relative to peers with potential upside from pipeline successes or targeted acquisitions
Risks
- Patent expirations and generic erosion for legacy products could pressure revenues over time
- Competitive pressure in HIV and other therapeutic areas from new entrants and next-generation therapies
- Regulatory and pricing pressure in the U.S. and Europe, including potential payer pushback on high-cost therapies
- Clinical or trial setbacks in pipeline assets could materially affect near-term sentiment and stock performance
- Insider selling activity (recent Form 4) and mixed social sentiment could weigh on short-term price action
- Macro/market risk: shifts in monetary policy or a risk-off move could reduce defensive flow benefits and increase volatility
Latest MarketMoodz coverage
- HSBC's Bullish Call on Gilead Leads Five Major Upgrades2026-07-06
- Gilead’s Trodelvy Clears First‑Line TNBC, Market Widens2026-06-25
- Gilead, Merck Halt Trodelvy–Keytruda Lung Trial; Market Impact2026-06-09
- Cramer: Nokia Has Room to Run with ~30% Upside2026-04-15
- Gilead Expands Tempus AI Partnership to Accelerate Oncology Pipeline2026-04-09
See today's live rating, score and targets
Members see the live hourly rating for GILD — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.